Recovery Plays: Moderna and Target Outpace S&P 500 Amid Sector Rotation

A notable shift in market sentiment is driving investors away from the artificial intelligence rally and toward defensive assets. Concerns over geopolitical instability in Iran and U.S. economic growth have prompted a rotation into healthcare and retail, sectors viewed as resilient regardless of macroeconomic volatility. Among the beneficiaries are Moderna (MRNA) and Target (TGT), both of which are recovering from multi-year downturns. These companies are leveraging strategic pivots and operational overhauls to regain investor confidence and outperform the broader S&P 500 index. Moderna, which saw peak revenues of $18 billion in 2022, experienced a 90% decline from its peak through the end of 2025. However, the biotech firm has pivoted toward a diversified pipeline focusing on oncology, rare diseases, and seasonal vaccines. With a reaffirmed revenue growth forecast of up to 10% for the current year, the stock has surged nearly 70% since January. Target is undergoing a strategic turnaround under new CEO Michael Fiddelke. The company is investing $2 billion this year to enhance store layouts, refresh product assortments, and improve employee training. This operational push has seen the stock rise over 20% year-to-date. From a valuation perspective, Target remains significantly cheaper than its peers, trading at 14x forward earnings compared to over 40x for competitors like Walmart and Costco. This valuation gap, combined with the rotation into staples, suggests a continuing trend toward value-oriented defensive plays.